Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription coactivator activity	NCOA2 NCOA3 KAT6A MED12L NR3C1 KAT6B MAML3 EP300	9.26e-07	303	51	8	GO:0003713
GeneOntologyMolecularFunction	structural constituent of postsynaptic actin cytoskeleton	POTEE POTEF POTEI	2.55e-06	11	51	3	GO:0098973
GeneOntologyMolecularFunction	acetyltransferase activity	NCOA3 ACAT1 KAT6A KAT6B EP300	6.76e-06	104	51	5	GO:0016407
GeneOntologyMolecularFunction	histone H3 acetyltransferase activity	KAT6A KAT6B EP300	6.99e-06	15	51	3	GO:0010484
GeneOntologyMolecularFunction	histone acetyltransferase activity	NCOA3 KAT6A KAT6B EP300	8.63e-06	51	51	4	GO:0004402
GeneOntologyMolecularFunction	peptide-lysine-N-acetyltransferase activity	NCOA3 KAT6A KAT6B EP300	1.17e-05	55	51	4	GO:0061733
GeneOntologyMolecularFunction	peptide N-acetyltransferase activity	NCOA3 KAT6A KAT6B EP300	1.66e-05	60	51	4	GO:0034212
GeneOntologyMolecularFunction	glycine:sodium symporter activity	SLC6A9 SLC6A5	1.92e-05	3	51	2	GO:0015375
GeneOntologyMolecularFunction	N-acetyltransferase activity	NCOA3 KAT6A KAT6B EP300	4.68e-05	78	51	4	GO:0008080
GeneOntologyMolecularFunction	structural constituent of postsynapse	POTEE POTEF POTEI	7.39e-05	32	51	3	GO:0099186
GeneOntologyMolecularFunction	transcription coregulator activity	NCOA2 NCOA3 KAT6A MED12L NR3C1 KAT6B MAML3 EP300	8.21e-05	562	51	8	GO:0003712
GeneOntologyMolecularFunction	transcription factor binding	NCOA2 FOXO1 NCOA3 AKAP8 KAT6A MED12L NR3C1 EP300 MEIS2	1.08e-04	753	51	9	GO:0008134
GeneOntologyMolecularFunction	N-acyltransferase activity	NCOA3 KAT6A KAT6B EP300	1.33e-04	102	51	4	GO:0016410
GeneOntologyMolecularFunction	structural constituent of synapse	POTEE POTEF POTEI	1.68e-04	42	51	3	GO:0098918
GeneOntologyMolecularFunction	neutral L-amino acid:sodium symporter activity	SLC6A9 SLC6A5	1.77e-04	8	51	2	GO:0005295
GeneOntologyMolecularFunction	histone H3K14 acetyltransferase activity	KAT6A KAT6B	2.28e-04	9	51	2	GO:0036408
GeneOntologyMolecularFunction	glycine transmembrane transporter activity	SLC6A9 SLC6A5	2.84e-04	10	51	2	GO:0015187
GeneOntologyMolecularFunction	histone modifying activity	NCOA3 ATR KAT6A KAT6B EP300	2.90e-04	229	51	5	GO:0140993
GeneOntologyMolecularFunction	structural constituent of cytoskeleton	POTEE POTEF ACTA1 POTEI	3.38e-04	130	51	4	GO:0005200
GeneOntologyMolecularFunction	acyltransferase activity, transferring groups other than amino-acyl groups	NCOA3 ACAT1 KAT6A KAT6B EP300	3.47e-04	238	51	5	GO:0016747
GeneOntologyMolecularFunction	chromatin binding	NCOA2 FOXO1 NCOA3 AKAP8 KAT6A NR3C1 KAT6B EP300	5.27e-04	739	51	8	GO:0003682
GeneOntologyMolecularFunction	nuclear glucocorticoid receptor binding	NCOA2 EP300	1.18e-03	20	51	2	GO:0035259
GeneOntologyMolecularFunction	peroxisome proliferator activated receptor binding	NCOA3 EP300	1.30e-03	21	51	2	GO:0042975
GeneOntologyMolecularFunction	histone H4 acetyltransferase activity	KAT6A EP300	1.56e-03	23	51	2	GO:0010485
GeneOntologyMolecularFunction	amino acid:sodium symporter activity	SLC6A9 SLC6A5	1.56e-03	23	51	2	GO:0005283
GeneOntologyMolecularFunction	carboxylic acid transmembrane transporter activity	SLC6A9 SLC22A6 SLC6A5 GRIK3	1.92e-03	207	51	4	GO:0046943
GeneOntologyMolecularFunction	organic acid transmembrane transporter activity	SLC6A9 SLC22A6 SLC6A5 GRIK3	1.95e-03	208	51	4	GO:0005342
GeneOntologyMolecularFunction	amino acid transmembrane transporter activity	SLC6A9 SLC6A5 GRIK3	2.45e-03	105	51	3	GO:0015171
GeneOntologyMolecularFunction	amino acid:monoatomic cation symporter activity	SLC6A9 SLC6A5	2.48e-03	29	51	2	GO:0005416
GeneOntologyMolecularFunction	nuclear androgen receptor binding	NCOA3 EP300	3.21e-03	33	51	2	GO:0050681
GeneOntologyMolecularFunction	nuclear thyroid hormone receptor binding	NCOA2 NCOA3	3.41e-03	34	51	2	GO:0046966
GeneOntologyMolecularFunction	beta-catenin binding	FOXO1 MED12L EP300	3.57e-03	120	51	3	GO:0008013
GeneOntologyMolecularFunction	organic acid:sodium symporter activity	SLC6A9 SLC6A5	3.61e-03	35	51	2	GO:0005343
GeneOntologyMolecularFunction	NF-kappaB binding	AKAP8 EP300	3.81e-03	36	51	2	GO:0051059
GeneOntologyMolecularFunction	carboxy-lyase activity	GAD1 UROD	3.81e-03	36	51	2	GO:0016831
GeneOntologyMolecularFunction	neutral L-amino acid transmembrane transporter activity	SLC6A9 SLC6A5	4.92e-03	41	51	2	GO:0015175
GeneOntologyMolecularFunction	organic anion transmembrane transporter activity	SLC6A9 SLC22A6 SLC6A5 GRIK3	6.61e-03	293	51	4	GO:0008514
GeneOntologyMolecularFunction	molecular adaptor activity	NCOA2 NCOA3 KAT6A MED12L NR3C1 KAT6B BAG6 MAML3 EP300	6.82e-03	1356	51	9	GO:0060090
GeneOntologyMolecularFunction	nuclear estrogen receptor binding	NCOA2 NCOA3	8.11e-03	53	51	2	GO:0030331
GeneOntologyMolecularFunction	transcription coactivator binding	FOXO1 EP300	8.41e-03	54	51	2	GO:0001223
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	NCOA2 NCOA3 KAT6A MED12L NR3C1 KAT6B MAML3 EP300	8.69e-03	1160	51	8	GO:0030674
GeneOntologyMolecularFunction	pyridoxal phosphate binding	GAD1 AGXT	9.02e-03	56	51	2	GO:0030170
GeneOntologyMolecularFunction	carbon-carbon lyase activity	GAD1 UROD	9.02e-03	56	51	2	GO:0016830
GeneOntologyMolecularFunction	vitamin B6 binding	GAD1 AGXT	9.33e-03	57	51	2	GO:0070279
GeneOntologyMolecularFunction	sodium ion transmembrane transporter activity	SLC6A9 SLC6A5 GRIK3	9.51e-03	171	51	3	GO:0015081
GeneOntologyMolecularFunction	nuclear receptor coactivator activity	NCOA2 NCOA3	1.06e-02	61	51	2	GO:0030374
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	NCOA2 FOXO1 NCOA3 BBX KLF18 ZNF217 NR3C1 EP300 MEIS2	1.08e-02	1459	51	9	GO:0000977
GeneOntologyMolecularFunction	Hsp70 protein binding	NR3C1 BAG6	1.13e-02	63	51	2	GO:0030544
GeneOntologyBiologicalProcess	positive regulation of intracellular steroid hormone receptor signaling pathway	NCOA2 NCOA3 NR3C1	1.13e-05	18	51	3	GO:0033145
GeneOntologyBiologicalProcess	protein acetylation	FOXO1 KAT6A BAG6 EP300	2.40e-05	68	51	4	GO:0006473
GeneOntologyBiologicalProcess	metanephric proximal tubule development	SLC22A6 ACAT1	3.59e-05	4	51	2	GO:0072237
GeneOntologyBiologicalProcess	response to hormone	NCOA2 FOXO1 CLDN18 NCOA3 AKAP8 ACAT1 TNFSF10 ACTA1 AGXT NR3C1 EP300	3.84e-05	1042	51	11	GO:0009725
GeneOntologyBiologicalProcess	muscle adaptation	FOXO1 CAMK2D ACTA1 NR3C1 EP300	5.23e-05	164	51	5	GO:0043500
GeneOntologyBiologicalProcess	synaptic transmission, glycinergic	SLC6A9 SLC6A5	5.97e-05	5	51	2	GO:0060012
GeneOntologyBiologicalProcess	postsynaptic actin cytoskeleton organization	POTEE POTEF POTEI	6.10e-05	31	51	3	GO:0098974
GeneOntologyBiologicalProcess	regulation of intracellular steroid hormone receptor signaling pathway	NCOA2 NCOA3 NR3C1 EP300	6.34e-05	87	51	4	GO:0033143
GeneOntologyBiologicalProcess	postsynaptic cytoskeleton organization	POTEE POTEF POTEI	8.81e-05	35	51	3	GO:0099188
GeneOntologyBiologicalProcess	glycine import across plasma membrane	SLC6A9 SLC6A5	8.93e-05	6	51	2	GO:1903804
GeneOntologyBiologicalProcess	positive regulation of glucocorticoid receptor signaling pathway	NCOA2 NR3C1	8.93e-05	6	51	2	GO:2000324
GeneOntologyBiologicalProcess	regulation of cardiac muscle hypertrophy	FOXO1 CAMK2D NR3C1 EP300	9.69e-05	97	51	4	GO:0010611
GeneOntologyBiologicalProcess	regulation of muscle hypertrophy	FOXO1 CAMK2D NR3C1 EP300	1.09e-04	100	51	4	GO:0014743
GeneOntologyBiologicalProcess	protein acylation	FOXO1 KAT6A BAG6 EP300	1.47e-04	108	51	4	GO:0043543
GeneOntologyBiologicalProcess	proximal tubule development	SLC22A6 ACAT1	2.66e-04	10	51	2	GO:0072014
GeneOntologyBiologicalProcess	positive regulation of cardiac muscle hypertrophy	CAMK2D NR3C1 EP300	3.23e-04	54	51	3	GO:0010613
GeneOntologyBiologicalProcess	regulation of muscle adaptation	FOXO1 CAMK2D NR3C1 EP300	3.26e-04	133	51	4	GO:0043502
GeneOntologyBiologicalProcess	regulation of glucose metabolic process	NCOA2 FOXO1 NR3C1 EP300	3.36e-04	134	51	4	GO:0010906
GeneOntologyBiologicalProcess	response to steroid hormone	NCOA2 NCOA3 ACTA1 AGXT NR3C1 EP300	3.41e-04	381	51	6	GO:0048545
GeneOntologyBiologicalProcess	positive regulation of muscle hypertrophy	CAMK2D NR3C1 EP300	3.41e-04	55	51	3	GO:0014742
GeneOntologyBiologicalProcess	nuclear receptor-mediated steroid hormone signaling pathway	NCOA2 NCOA3 NR3C1 EP300	3.55e-04	136	51	4	GO:0030518
GeneOntologyBiologicalProcess	cell growth involved in cardiac muscle cell development	CAMK2D NR3C1 EP300	3.60e-04	56	51	3	GO:0061049
GeneOntologyBiologicalProcess	physiological muscle hypertrophy	CAMK2D NR3C1 EP300	3.60e-04	56	51	3	GO:0003298
GeneOntologyBiologicalProcess	physiological cardiac muscle hypertrophy	CAMK2D NR3C1 EP300	3.60e-04	56	51	3	GO:0003301
GeneOntologyBiologicalProcess	internal peptidyl-lysine acetylation	BAG6 EP300	3.89e-04	12	51	2	GO:0018393
GeneOntologyBiologicalProcess	regulation of glucocorticoid receptor signaling pathway	NCOA2 NR3C1	3.89e-04	12	51	2	GO:2000322
GeneOntologyBiologicalProcess	cardiac muscle hypertrophy	FOXO1 CAMK2D NR3C1 EP300	4.19e-04	142	51	4	GO:0003300
GeneOntologyBiologicalProcess	striated muscle hypertrophy	FOXO1 CAMK2D NR3C1 EP300	4.65e-04	146	51	4	GO:0014897
GeneOntologyBiologicalProcess	muscle hypertrophy	FOXO1 CAMK2D NR3C1 EP300	4.89e-04	148	51	4	GO:0014896
GeneOntologyBiologicalProcess	carboxylic acid transport	ACSL4 SLC6A9 SLC22A6 AGXT SLC6A5 NR3C1	5.03e-04	410	51	6	GO:0046942
GeneOntologyBiologicalProcess	organic acid transport	ACSL4 SLC6A9 SLC22A6 AGXT SLC6A5 NR3C1	5.16e-04	412	51	6	GO:0015849
GeneOntologyBiologicalProcess	steroid hormone receptor signaling pathway	NCOA2 NCOA3 NR3C1 EP300	5.82e-04	155	51	4	GO:0043401
GeneOntologyBiologicalProcess	internal protein amino acid acetylation	BAG6 EP300	6.17e-04	15	51	2	GO:0006475
GeneOntologyBiologicalProcess	glycine transport	SLC6A9 SLC6A5	6.17e-04	15	51	2	GO:0015816
GeneOntologyBiologicalProcess	replicative senescence	ROMO1 ATR	7.04e-04	16	51	2	GO:0090399
GeneOntologyBiologicalProcess	regulation of cellular response to heat	ATR EP300	7.04e-04	16	51	2	GO:1900034
GeneOntologyBiologicalProcess	regulation of gluconeogenesis	FOXO1 NR3C1 EP300	7.23e-04	71	51	3	GO:0006111
GeneOntologyBiologicalProcess	nuclear receptor-mediated glucocorticoid signaling pathway	NCOA2 NR3C1	7.96e-04	17	51	2	GO:0042921
GeneOntologyBiologicalProcess	nuclear receptor-mediated corticosteroid signaling pathway	NCOA2 NR3C1	8.94e-04	18	51	2	GO:0031958
GeneOntologyBiologicalProcess	positive regulation of cell growth involved in cardiac muscle cell development	NR3C1 EP300	1.11e-03	20	51	2	GO:0061051
GeneOntologyCellularComponent	histone acetyltransferase complex	POTEE POTEF KAT6A POTEI KAT6B EP300	1.36e-07	94	53	6	GO:0000123
GeneOntologyCellularComponent	protein acetyltransferase complex	POTEE POTEF KAT6A POTEI KAT6B EP300	2.49e-07	104	53	6	GO:0031248
GeneOntologyCellularComponent	acetyltransferase complex	POTEE POTEF KAT6A POTEI KAT6B EP300	3.29e-07	109	53	6	GO:1902493
GeneOntologyCellularComponent	chromatin	NCOA2 FOXO1 POTEE NCOA3 BBX AKAP8 POTEF KAT6A POTEI NR3C1 KAT6B EP300 MEIS2	6.18e-05	1480	53	13	GO:0000785
GeneOntologyCellularComponent	NuA4 histone acetyltransferase complex	POTEE POTEF POTEI	7.25e-05	32	53	3	GO:0035267
GeneOntologyCellularComponent	H4/H2A histone acetyltransferase complex	POTEE POTEF POTEI	7.25e-05	32	53	3	GO:0043189
GeneOntologyCellularComponent	MOZ/MORF histone acetyltransferase complex	KAT6A KAT6B	1.31e-04	7	53	2	GO:0070776
GeneOntologyCellularComponent	H3 histone acetyltransferase complex	KAT6A KAT6B	1.75e-04	8	53	2	GO:0070775
GeneOntologyCellularComponent	H4 histone acetyltransferase complex	POTEE POTEF POTEI	2.03e-04	45	53	3	GO:1902562
GeneOntologyCellularComponent	cerebellar climbing fiber to Purkinje cell synapse	ADGRB3 PLXNA4	3.42e-04	11	53	2	GO:0150053
GeneOntologyCellularComponent	actin filament	POTEE POTEF ACTA1 POTEI	5.13e-04	146	53	4	GO:0005884
GeneOntologyCellularComponent	nuclear speck	KAT6A ZNF217 NR3C1 SRRM2 PNISR MAML3	7.51e-04	431	53	6	GO:0016607
GeneOntologyCellularComponent	asymmetric, glutamatergic, excitatory synapse	ADGRB3 PLXNA4	1.68e-03	24	53	2	GO:0098985
GeneOntologyCellularComponent	nuclear body	NCOA2 ATR KAT6A ZNF217 NR3C1 SRRM2 PNISR MAML3	1.85e-03	903	53	8	GO:0016604
GeneOntologyCellularComponent	excitatory synapse	SLC6A9 ADGRB3 PLXNA4	2.54e-03	107	53	3	GO:0060076
GeneOntologyCellularComponent	intracellular protein-containing complex	POTEE POTEF CAMK2D KAT6A PSMB6 POTEI KAT6B EP300	2.93e-03	972	53	8	GO:0140535
HumanPheno	Thin vermilion border	ACSL4 GAD1 KAT6A MED12L KAT6B SRRM2 EP300 MEIS2	3.12e-05	433	17	8	HP:0000233
HumanPheno	Thin upper lip vermilion	GAD1 KAT6A MED12L KAT6B SRRM2 EP300 MEIS2	5.90e-05	339	17	7	HP:0000219
HumanPheno	Thin lips	GAD1 KAT6A MED12L KAT6B SRRM2 EP300 MEIS2	5.90e-05	339	17	7	HP:0000213
HumanPheno	Sparse eyebrow	GAD1 ATR KAT6A MED12L MEIS2	9.94e-05	151	17	5	HP:0045075
HumanPheno	Laryngomalacia	KAT6A KAT6B EP300 MEIS2	1.39e-04	84	17	4	HP:0001601
HumanPheno	Upper eyelid edema	KAT6A MED12L	1.56e-04	6	17	2	HP:0012724
HumanPheno	Abnormal external nose morphology	ACSL4 SLC6A9 GAD1 ATR KAT6A MED12L KAT6B SRRM2 EP300 MEIS2	1.93e-04	916	17	10	HP:0010938
Domain	Actin_CS	POTEE POTEF ACTA1 POTEI	8.76e-08	16	51	4	IPR004001
Domain	ACTINS_2	POTEE POTEF ACTA1 POTEI	1.14e-07	17	51	4	PS00432
Domain	Actin/actin-like_CS	POTEE POTEF ACTA1 POTEI	1.47e-07	18	51	4	IPR020902
Domain	ACTINS_ACT_LIKE	POTEE POTEF ACTA1 POTEI	1.85e-07	19	51	4	PS01132
Domain	Nuc_rcpt_coact	NCOA2 NCOA3 EP300	3.81e-07	6	51	3	IPR009110
Domain	Actin	POTEE POTEF ACTA1 POTEI	1.47e-06	31	51	4	IPR004000
Domain	Actin	POTEE POTEF ACTA1 POTEI	1.47e-06	31	51	4	PF00022
Domain	ACTIN	POTEE POTEF ACTA1 POTEI	1.47e-06	31	51	4	SM00268
Domain	DUF4927	NCOA2 NCOA3	7.31e-06	2	51	2	PF16279
Domain	DUF4927	NCOA2 NCOA3	7.31e-06	2	51	2	IPR032565
Domain	DUF1518	NCOA2 NCOA3	2.19e-05	3	51	2	PF07469
Domain	DUF1518	NCOA2 NCOA3	2.19e-05	3	51	2	IPR010011
Domain	Nuc_rcpt_coact_Ncoa-typ	NCOA2 NCOA3	2.19e-05	3	51	2	IPR014920
Domain	SRC-1	NCOA2 NCOA3	2.19e-05	3	51	2	IPR014935
Domain	Src1_rcpt_coact	NCOA2 NCOA3	2.19e-05	3	51	2	IPR008955
Domain	Nuclear_rcpt_coactivator	NCOA2 NCOA3	2.19e-05	3	51	2	IPR017426
Domain	DUF1518	NCOA2 NCOA3	2.19e-05	3	51	2	SM01151
Domain	SRC-1	NCOA2 NCOA3	2.19e-05	3	51	2	PF08832
Domain	-	NCOA2 NCOA3	2.19e-05	3	51	2	4.10.630.10
Domain	Nuc_rec_co-act	NCOA2 NCOA3	2.19e-05	3	51	2	PF08815
Domain	MOZ_SAS	KAT6A KAT6B	7.27e-05	5	51	2	PF01853
Domain	HAT_MYST-type	KAT6A KAT6B	7.27e-05	5	51	2	IPR002717
Domain	MYST_HAT	KAT6A KAT6B	7.27e-05	5	51	2	PS51726
Domain	H15	KAT6A KAT6B	5.59e-04	13	51	2	SM00526
Domain	H15	KAT6A KAT6B	5.59e-04	13	51	2	PS51504
Domain	Histone_H1/H5_H15	KAT6A KAT6B	6.51e-04	14	51	2	IPR005818
Domain	NA_NEUROTRAN_SYMP_2	SLC6A9 SLC6A5	1.09e-03	18	51	2	PS00754
Domain	SNF	SLC6A9 SLC6A5	1.21e-03	19	51	2	PF00209
Domain	NA_NEUROTRAN_SYMP_1	SLC6A9 SLC6A5	1.21e-03	19	51	2	PS00610
Domain	NA_NEUROTRAN_SYMP_3	SLC6A9 SLC6A5	1.21e-03	19	51	2	PS50267
Domain	Na/ntran_symport	SLC6A9 SLC6A5	1.21e-03	19	51	2	IPR000175
Domain	PAS	NCOA2 NCOA3	2.11e-03	25	51	2	PF00989
Domain	PAS_fold	NCOA2 NCOA3	2.11e-03	25	51	2	IPR013767
Domain	PAS	NCOA2 NCOA3	3.44e-03	32	51	2	SM00091
Domain	PAS	NCOA2 NCOA3	3.88e-03	34	51	2	IPR000014
Domain	PAS	NCOA2 NCOA3	3.88e-03	34	51	2	PS50112
Domain	-	GAD1 AGXT	4.11e-03	35	51	2	3.90.1150.10
Domain	PyrdxlP-dep_Trfase_major_sub2	GAD1 AGXT	4.34e-03	36	51	2	IPR015422
Domain	-	GAD1 AGXT	5.08e-03	39	51	2	3.40.640.10
Domain	-	KAT6A KAT6B	5.34e-03	40	51	2	3.40.630.30
Pathway	PID_AR_TF_PATHWAY	NCOA2 FOXO1 NR3C1 EP300	1.07e-05	53	37	4	M151
Pathway	WP_NUCLEAR_RECEPTORS_METAPATHWAY	NCOA2 FOXO1 SLC6A9 NCOA3 SLC6A5 NR3C1 EP300	1.48e-05	314	37	7	M39428
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION	FOXO1 PLXNA4 NR3C1 EP300	2.58e-05	66	37	4	M27938
Pathway	PID_SMAD2_3NUCLEAR_PATHWAY	NCOA2 FOXO1 NR3C1 EP300	6.07e-05	82	37	4	M2
Pathway	PID_RETINOIC_ACID_PATHWAY	NCOA2 NCOA3 EP300	6.44e-05	30	37	3	M207
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_OXIDATIVE_STRESS_METABOLIC_AND_NEURONAL_GENES	FOXO1 PLXNA4 NR3C1	6.44e-05	30	37	3	M27941
Pathway	WP_PREGNANE_X_RECEPTOR_PATHWAY	NCOA2 FOXO1 NCOA3	7.83e-05	32	37	3	M39567
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA2 FOXO1 NCOA3 EP300	9.12e-05	91	37	4	M39700
Pathway	REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION	FOXO1 EP300	9.99e-05	6	37	2	MM15660
Pathway	REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	FOXO1 MAML3 EP300	1.78e-04	42	37	3	M17541
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	NCOA2 KAT6A KAT6B	2.34e-04	46	37	3	MM14935
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML3 EP300	2.98e-04	10	37	2	MM15535
Pathway	REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION	FOXO1 EP300	2.98e-04	10	37	2	M27945
Pathway	KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	NCOA2 NCOA3	3.63e-04	11	37	2	M47503
Pathway	WP_ALANINE_AND_ASPARTATE_METABOLISM	GAD1 AGXT	4.35e-04	12	37	2	M39331
Pathway	REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML3 EP300	4.35e-04	12	37	2	M27159
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	NCOA2 KAT6A KAT6B EP300	5.03e-04	142	37	4	M27233
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML3 EP300	5.98e-04	14	37	2	M27808
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	NCOA2 NCOA3 ZNF217 EP300	6.04e-04	149	37	4	M27888
Pathway	PID_ERA_GENOMIC_PATHWAY	NCOA2 NCOA3 EP300	6.21e-04	64	37	3	M200
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	KAT6A MAML3 EP300	6.50e-04	65	37	3	M39682
Pathway	WP_ALANINE_AND_ASPARTATE_METABOLISM	GAD1 AGXT	6.89e-04	15	37	2	MM15960
Pathway	PID_ERB_GENOMIC_PATHWAY	NCOA2 NCOA3	6.89e-04	15	37	2	M119
Pathway	WP_RUBINSTEINTAYBI_SYNDROME_1	FOXO1 NCOA3	6.89e-04	15	37	2	M48323
Pathway	KEGG_MEDICUS_REFERENCE_P300_P21_CELL_CYCLE_G1_S	ATR EP300	6.89e-04	15	37	2	M47524
Pathway	REACTOME_FORMATION_OF_PARAXIAL_MESODERM	PSMB6 MAML3 EP300	7.74e-04	69	37	3	M46439
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	MAML3 EP300	7.86e-04	16	37	2	M27121
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES	FOXO1 EP300	7.86e-04	16	37	2	M27940
Pathway	PID_AP1_PATHWAY	ACTA1 NR3C1 EP300	8.07e-04	70	37	3	M167
Pathway	REACTOME_CIRCADIAN_CLOCK	NCOA2 NR3C1 EP300	8.07e-04	70	37	3	M938
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	NCOA2 EP300	9.99e-04	18	37	2	M26942
Pathway	WP_2Q211_COPY_NUMBER_VARIATION_SYNDROME	POTEE FAM168B	9.99e-04	18	37	2	M45539
Pathway	REACTOME_SIGNALING_BY_NOTCH1	MAML3 EP300	9.99e-04	18	37	2	MM14775
Pathway	REACTOME_TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS	SLC6A9 SLC22A6 SLC6A5	1.03e-03	76	37	3	MM15072
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	PSMB6 MAML3 EP300	1.03e-03	76	37	3	MM15520
Pathway	REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS	SLC6A9 SLC6A5	1.11e-03	19	37	2	M27362
Pathway	REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS	SLC6A9 SLC6A5	1.11e-03	19	37	2	MM15107
Pathway	REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML3 EP300	1.24e-03	20	37	2	M27881
Pathway	REACTOME_SIGNALING_BY_NOTCH4	PSMB6 MAML3 EP300	1.28e-03	82	37	3	M594
Pathway	PID_REG_GR_PATHWAY	NCOA2 NR3C1 EP300	1.28e-03	82	37	3	M115
Pathway	REACTOME_TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS	SLC6A9 SLC22A6 SLC6A5	1.37e-03	84	37	3	M27334
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	NCOA2 NCOA3 EP300	1.37e-03	84	37	3	M1008
Pathway	BIOCARTA_G2_PATHWAY	ATR EP300	1.50e-03	22	37	2	MM1365
Pathway	BIOCARTA_VDR_PATHWAY	NCOA3 EP300	1.50e-03	22	37	2	MM1370
Pathway	BIOCARTA_NTHI_PATHWAY	NR3C1 EP300	1.50e-03	22	37	2	MM1443
Pathway	WP_TRANSCRIPTION_FACTOR_REGULATION_IN_ADIPOGENESIS	FOXO1 NR3C1	1.50e-03	22	37	2	M39414
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION	FOXO1 EP300	1.50e-03	22	37	2	MM15656
Pathway	BIOCARTA_NTHI_PATHWAY	NR3C1 EP300	1.64e-03	23	37	2	M2821
Pathway	REACTOME_HSF1_DEPENDENT_TRANSACTIVATION	CAMK2D EP300	1.64e-03	23	37	2	MM14953
Pathway	BIOCARTA_G2_PATHWAY	ATR EP300	1.78e-03	24	37	2	M8560
Pathway	REACTOME_MAPK6_MAPK4_SIGNALING	FOXO1 NCOA3 PSMB6	1.84e-03	93	37	3	M27572
Pathway	REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML3 EP300	1.94e-03	25	37	2	M27880
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	PSMB6 MAML3 EP300	2.01e-03	96	37	3	M27784
Pathway	PID_HDAC_CLASSIII_PATHWAY	FOXO1 EP300	2.09e-03	26	37	2	M32
Pathway	REACTOME_CELLULAR_RESPONSE_TO_HEAT_STRESS	ATR CAMK2D EP300	2.32e-03	101	37	3	M27253
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION	FOXO1 GAD1 ATR CAMK2D KAT6A PSMB6 PLXNA4 NR3C1 MAML3 EP300	2.40e-03	1387	37	10	M734
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	NCOA2 NCOA3 ZNF217 EP300	2.55e-03	220	37	4	M27794
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	KAT6A EP300	2.60e-03	29	37	2	MM15340
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	KAT6A EP300	2.78e-03	30	37	2	M27637
Pathway	REACTOME_ADIPOGENESIS	NCOA2 NCOA3 EP300	2.96e-03	110	37	3	M48259
Pathway	WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY	NCOA2 FOXO1	2.97e-03	31	37	2	M39476
Pathway	WP_WHITE_FAT_CELL_DIFFERENTIATION	FOXO1 NR3C1	3.16e-03	32	37	2	M39333
Pathway	KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM	GAD1 AGXT	3.16e-03	32	37	2	M17758
Pubmed	Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes.	NCOA2 NCOA3 ATR ACTA1 SRRM2 EP300	3.73e-09	85	53	6	16051665
Pubmed	New nomenclature for chromatin-modifying enzymes.	NCOA2 NCOA3 KAT6A KAT6B EP300	2.67e-08	57	53	5	18022353
Pubmed	Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication.	KAT6A KAT6B EP300	3.33e-08	5	53	3	17182677
Pubmed	Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.	NCOA2 NCOA3 EP300	3.33e-08	5	53	3	12714702
Pubmed	SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4.	NCOA2 NCOA3 EP300	3.33e-08	5	53	3	9812974
Pubmed	Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly.	NCOA2 NCOA3 EP300	6.66e-08	6	53	3	16923966
Pubmed	Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.	NCOA2 NR3C1 EP300	1.16e-07	7	53	3	9590696
Pubmed	An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors.	NCOA2 NR3C1 EP300	1.16e-07	7	53	3	9920895
Pubmed	The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine.	NCOA2 NCOA3 EP300	1.16e-07	7	53	3	12709428
Pubmed	The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment.	NCOA2 NCOA3 EP300	1.86e-07	8	53	3	12082103
Pubmed	Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu.	NCOA2 NCOA3 EP300	1.86e-07	8	53	3	14747462
Pubmed	Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.	NCOA2 NCOA3 EP300	1.86e-07	8	53	3	10490106
Pubmed	Regulation of somatic growth by the p160 coactivator p/CIP.	NCOA2 NCOA3 EP300	2.79e-07	9	53	3	11087842
Pubmed	The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.	ATR NR3C1 EP300	3.98e-07	10	53	3	20347598
Pubmed	Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex.	NCOA2 NCOA3 NR3C1	5.47e-07	11	53	3	11704662
Pubmed	The Hippocampal Response to Acute Corticosterone Elevation Is Altered in a Mouse Model for Angelman Syndrome.	NCOA2 NCOA3 NR3C1	5.47e-07	11	53	3	36613751
Pubmed	Acetylation of HIV-1 integrase by p300 regulates viral integration.	KAT6A KAT6B EP300	5.47e-07	11	53	3	16096645
Pubmed	Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol.	GAD1 SLC6A5 GRIK3	9.45e-07	13	53	3	20859245
Pubmed	Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140.	NCOA2 NCOA3 NR3C1	9.45e-07	13	53	3	11266503
Pubmed	Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.	NCOA2 NCOA3 EP300	1.20e-06	14	53	3	11500849
Pubmed	Cerebellar nuclei excitatory neurons regulate developmental scaling of presynaptic Purkinje cell number and organ growth.	GAD1 SLC6A5 MEIS2	1.20e-06	14	53	3	31742552
Pubmed	Identification of a novel actin isoform in hepatocellular carcinoma.	POTEE POTEF POTEI	1.50e-06	15	53	3	16824795
Pubmed	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.	NCOA2 NCOA3 EP300	2.24e-06	17	53	3	19183483
Pubmed	BAG6/BAT3 modulates autophagy by affecting EP300/p300 intracellular localization.	BAG6 EP300	2.28e-06	2	53	2	24852146
Pubmed	Molecular biology of mammalian amino acid transporters.	SLC6A9 SLC6A5	2.28e-06	2	53	2	8811182
Pubmed	Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain.	SLC6A9 SLC6A5	2.28e-06	2	53	2	8667011
Pubmed	Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.	NCOA2 KAT6A	2.28e-06	2	53	2	26854485
Pubmed	Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis.	NCOA2 NCOA3	2.28e-06	2	53	2	21220509
Pubmed	Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions.	NCOA2 NCOA3	2.28e-06	2	53	2	30273195
Pubmed	Binding of the N-terminal region of coactivator TIF2 to the intrinsically disordered AF1 domain of the glucocorticoid receptor is accompanied by conformational reorganizations.	NCOA2 NR3C1	2.28e-06	2	53	2	23132854
Pubmed	Ep300 sequestration to functionally distinct glucocorticoid receptor binding loci underlie rapid gene activation and repression.	NR3C1 EP300	2.28e-06	2	53	2	35713523
Pubmed	A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance.	NCOA2 NR3C1	2.28e-06	2	53	2	17635946
Pubmed	A primate-specific POTE-actin fusion protein plays a role in apoptosis.	POTEE POTEF	2.28e-06	2	53	2	19669888
Pubmed	Isolation and characterization of cDNA clones from mouse skeletal muscle actin mRNA.	ACAT1 ACTA1	2.28e-06	2	53	2	3013550
Pubmed	Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease.	KAT6A KAT6B	2.28e-06	2	53	2	27185879
Pubmed	Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition.	NCOA2 NR3C1	2.28e-06	2	53	2	12151000
Pubmed	Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes.	NCOA2 NR3C1	2.28e-06	2	53	2	23159735
Pubmed	No association of alcohol dependence with SLC6A5 and SLC6A9 glycine transporter polymorphisms.	SLC6A9 SLC6A5	2.28e-06	2	53	2	19650813
Pubmed	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells.	NCOA2 NCOA3	2.28e-06	2	53	2	30048685
Pubmed	A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.	NCOA2 KAT6A	2.28e-06	2	53	2	9558366
Pubmed	MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).	KAT6A EP300	2.28e-06	2	53	2	10824998
Pubmed	Cloning, functional characterisation and population analysis of a variant form of the human glycine type 2 transporter.	SLC6A9 SLC6A5	2.28e-06	2	53	2	10606742
Pubmed	ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B.	KAT6A KAT6B	2.28e-06	2	53	2	39505971
Pubmed	Glycine transporter isoforms show differential subcellular localization in PC12 cells.	SLC6A9 SLC6A5	2.28e-06	2	53	2	12091465
Pubmed	NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia.	NCOA3 KAT6A	2.28e-06	2	53	2	17805331
Pubmed	A novel mutation of the hGR gene causing Chrousos syndrome.	NCOA2 NR3C1	2.28e-06	2	53	2	26031419
Pubmed	Acetylation curtails nucleosome binding, not stable nucleosome remodeling, by FoxO1.	FOXO1 EP300	2.28e-06	2	53	2	19146829
Pubmed	A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity.	NCOA2 NR3C1	2.28e-06	2	53	2	15769988
Pubmed	Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis.	NCOA2 NCOA3	2.28e-06	2	53	2	26040939
Pubmed	The double PHD finger domain of MOZ/MYST3 induces α-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification.	KAT6A KAT6B	2.28e-06	2	53	2	24150941
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	NCOA3 SYNRG AKAP8 ATR ZNF217 KAT6B SRRM2 PNISR BAG6	2.36e-06	774	53	9	15302935
Pubmed	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.	NCOA2 NCOA3 EP300	3.74e-06	20	53	3	11877444
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA2 NCOA3 EP300	4.36e-06	21	53	3	19596656
Pubmed	The Vertebrate Genome Annotation browser 10 years on.	POTEE POTEF POTEI SRRM2 MEIS2	5.09e-06	163	53	5	24316575
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	SCFD2 NCOA2 ACSL4 NCOA3 NR3C1 MAML3 TMEM200A EP300	5.26e-06	638	53	8	31182584
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	NCOA2 NCOA3 ROMO1 AKAP8 ACAT1 MAML3 EP300	5.91e-06	457	53	7	32344865
Pubmed	Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1.	NCOA2 NR3C1	6.83e-06	3	53	2	15557560
Pubmed	MORF and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain.	KAT6A KAT6B	6.83e-06	3	53	2	36754959
Pubmed	The transcriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles.	NCOA2 NCOA3	6.83e-06	3	53	2	21035760
Pubmed	Targeted ablation, silencing, and activation establish glycinergic dorsal horn neurons as key components of a spinal gate for pain and itch.	GAD1 SLC6A5	6.83e-06	3	53	2	25789756
Pubmed	Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.	NCOA2 NCOA3	6.83e-06	3	53	2	21059860
Pubmed	Enhancing Acsl4 in absence of mTORC2/Rictor drove β-cell dedifferentiation via inhibiting FoxO1 and promoting ROS production.	FOXO1 ACSL4	6.83e-06	3	53	2	34455055
Pubmed	The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6.	NCOA3 EP300	6.83e-06	3	53	2	15145939
Pubmed	Transport activities and expression patterns of glycine transporters 1 and 2 in the developing murine brain stem and spinal cord.	SLC6A9 SLC6A5	6.83e-06	3	53	2	22695116
Pubmed	HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53.	BAG6 EP300	6.83e-06	3	53	2	17403783
Pubmed	The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription.	FOXO1 EP300	6.83e-06	3	53	2	15890677
Pubmed	Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.	NCOA2 NCOA3	6.83e-06	3	53	2	21735116
Pubmed	The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.	FOXO1 NR3C1	6.83e-06	3	53	2	18612045
Pubmed	Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.	NCOA2 NCOA3	6.83e-06	3	53	2	16675958
Pubmed	FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors.	NCOA2 NCOA3	6.83e-06	3	53	2	15698540
Pubmed	Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene.	NCOA2 NCOA3	6.83e-06	3	53	2	9506940
Pubmed	Glucocorticoid receptor interacting protein-1 restores glucocorticoid responsiveness in steroid-resistant airway structural cells.	NCOA2 NR3C1	6.83e-06	3	53	2	19805480
Pubmed	Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers.	NCOA2 NCOA3	6.83e-06	3	53	2	28390937
Pubmed	Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.	NCOA2 NCOA3	6.83e-06	3	53	2	19277704
Pubmed	Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences.	NCOA2 NCOA3	6.83e-06	3	53	2	23927929
Pubmed	Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation.	NCOA2 NCOA3	6.83e-06	3	53	2	19052561
Pubmed	The cleft palate candidate gene BAG6 supports FoxO1 acetylation to promote FasL-mediated apoptosis during palate fusion.	FOXO1 BAG6	6.83e-06	3	53	2	32991875
Pubmed	p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint.	ATR EP300	6.83e-06	3	53	2	17272271
Pubmed	The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription.	NCOA3 EP300	6.83e-06	3	53	2	12569362
Pubmed	Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration.	TNFSF10 EP300	6.83e-06	3	53	2	22415975
Pubmed	The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression.	NCOA2 NR3C1	6.83e-06	3	53	2	16362036
Pubmed	Characterization of the interactions between the glycine transporters GLYT1 and GLYT2 and the SNARE protein syntaxin 1A.	SLC6A9 SLC6A5	6.83e-06	3	53	2	10722844
Pubmed	Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators.	NCOA3 EP300	6.83e-06	3	53	2	11823864
Pubmed	Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.	NCOA2 NCOA3	6.83e-06	3	53	2	18845648
Pubmed	The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.	NCOA2 NCOA3	6.83e-06	3	53	2	12138202
Pubmed	Evolution and expression of chimeric POTE-actin genes in the human genome.	POTEE POTEF	6.83e-06	3	53	2	17101985
Pubmed	AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor.	NCOA3 EP300	6.83e-06	3	53	2	10866661
Pubmed	Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.	KAT6A KAT6B	6.83e-06	3	53	2	23063713
Pubmed	The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1.	NCOA2 NCOA3	6.83e-06	3	53	2	11923473
Pubmed	Structure and chromosomal locations of mouse steroid receptor coactivator gene family.	NCOA2 NCOA3	6.83e-06	3	53	2	10501088
Pubmed	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.	FOXO1 EP300	6.83e-06	3	53	2	27132507
Pubmed	Involvement of GR and p300 in the induction of H6PD by cortisol in human amnion fibroblasts.	NR3C1 EP300	6.83e-06	3	53	2	23125313
Pubmed	MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.	NCOA2 KAT6A	6.83e-06	3	53	2	12676584
Pubmed	The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism.	NCOA2 NCOA3	6.83e-06	3	53	2	16423883
Pubmed	Control of Foxo1 gene expression by co-activator P300.	FOXO1 EP300	6.83e-06	3	53	2	24379407
Pubmed	Vpr and its interactions with cellular proteins.	ATR NR3C1 EP300	1.07e-05	28	53	3	20012529
Pubmed	Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action.	NCOA2 NCOA3 EP300	1.07e-05	28	53	3	24880616
Pubmed	The CRL4DCAF6 E3 ligase ubiquitinates CtBP1/2 to induce apoptotic signalling and promote intervertebral disc degeneration.	GAD1 NR3C1 SRRM2 BAG6 EP300	1.34e-05	199	53	5	36688959
Pubmed	miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.	NCOA2 NCOA3	1.36e-05	4	53	2	26066330
Pubmed	Macromolecular translocation inhibitor II (Zn(2+)-binding protein, parathymosin) interacts with the glucocorticoid receptor and enhances transcription in vivo.	NR3C1 EP300	1.36e-05	4	53	2	16150697
Interaction	ETV1 interactions	NCOA2 NCOA3 ATR EP300	6.44e-07	29	48	4	int:ETV1
Interaction	TLE3 interactions	NCOA2 NCOA3 AKAP8 ACTA1 ZNF217 NR3C1 SRRM2 EP300	2.68e-06	376	48	8	int:TLE3
Interaction	TLX1 interactions	NCOA2 NCOA3 KAT6A ZNF217 EP300 MEIS2	3.57e-06	175	48	6	int:TLX1
Interaction	ACTG2 interactions	POTEE POTEF ACTA1 POTEI	5.55e-06	49	48	4	int:ACTG2
Interaction	POTEJ interactions	POTEE ACTA1 POTEI NR3C1	7.05e-06	52	48	4	int:POTEJ
Interaction	NCOA2 interactions	NCOA2 NCOA3 ATR NR3C1 EP300	2.10e-05	141	48	5	int:NCOA2
Interaction	NCOA1 interactions	NCOA2 FOXO1 NCOA3 NR3C1 EP300	2.48e-05	146	48	5	int:NCOA1
Interaction	FMR1 interactions	NCOA2 POTEE NCOA3 AKAP8 CAMK2D KAT6A NR3C1 MSI2	3.51e-05	536	48	8	int:FMR1
Interaction	FOXJ2 interactions	NCOA2 BBX AKAP8 NR3C1	4.12e-05	81	48	4	int:FOXJ2
Interaction	SIRT2 interactions	SCFD2 FOXO1 NCOA3 ATR EP300	4.46e-05	165	48	5	int:SIRT2
Interaction	NUP35 interactions	NCOA2 NCOA3 ROMO1 AKAP8 ACAT1 MAML3 EP300	6.07e-05	424	48	7	int:NUP35
Interaction	ELP1 interactions	CAMK2D ZNF217 NR3C1 BAG6 EP300	7.11e-05	182	48	5	int:ELP1
Interaction	THRB interactions	NCOA2 FOXO1 NCOA3 SLC22A6 EP300	7.88e-05	186	48	5	int:THRB
Interaction	H3-4 interactions	NCOA2 NCOA3 TNFSF10 KAT6A ZNF217 KAT6B EP300	8.57e-05	448	48	7	int:H3-4
Interaction	TBX4 interactions	NCOA3 NR3C1	1.16e-04	7	48	2	int:TBX4
Interaction	ERRFI1 interactions	POTEE POTEF ACTA1 PSMB6	1.22e-04	107	48	4	int:ERRFI1
Interaction	KLF8 interactions	NCOA2 NCOA3 AKAP8 PSMB6 ZNF217 EP300	1.25e-04	329	48	6	int:KLF8
Interaction	TES interactions	AKAP8 POTEF ACTA1 NR3C1 BAG6 EP300	1.31e-04	332	48	6	int:TES
Interaction	NR4A1 interactions	NCOA2 NCOA3 AKAP8 NR3C1 EP300	1.46e-04	212	48	5	int:NR4A1
Interaction	MYCBP interactions	AKAP8 POTEF KAT6A UROD	1.51e-04	113	48	4	int:MYCBP
Interaction	TBR1 interactions	NCOA2 NCOA3 ZNF217 EP300	1.51e-04	113	48	4	int:TBR1
Interaction	AGXT interactions	FAM168B ACAT1 AGXT	1.57e-04	44	48	3	int:AGXT
Interaction	RARB interactions	NCOA3 NR3C1 EP300	1.79e-04	46	48	3	int:RARB
Interaction	NR3C2 interactions	ACTA1 NR3C1 EP300	1.79e-04	46	48	3	int:NR3C2
Interaction	NCOA3 interactions	NCOA2 NCOA3 ACTA1 NR3C1 EP300	1.88e-04	224	48	5	int:NCOA3
Interaction	NR1I2 interactions	NCOA2 NCOA3 EP300	2.03e-04	48	48	3	int:NR1I2
Interaction	YWHAH interactions	NCOA2 FOXO1 NCOA3 SYNRG AKAP8 NHSL2 POTEF NR3C1 SRRM2 SMAP2	2.24e-04	1102	48	10	int:YWHAH
Interaction	ACTA1 interactions	POTEE NCOA3 POTEF ACTA1 POTEI EP300	2.39e-04	371	48	6	int:ACTA1
Interaction	AP1B1 interactions	SYNRG ATR NR3C1 SMAP2 EP300	2.44e-04	237	48	5	int:AP1B1
Interaction	EWSR1 interactions	NCOA3 AKAP8 ACAT1 POTEF KAT6A ZNF217 PNISR BAG6 EP300	2.49e-04	906	48	9	int:EWSR1
Interaction	PAX9 interactions	NCOA2 NCOA3 ZNF217 EP300	2.58e-04	130	48	4	int:PAX9
Interaction	MEF2C interactions	NCOA2 NCOA3 EP300	2.89e-04	54	48	3	int:MEF2C
Interaction	PFDN2 interactions	FOXO1 POTEE POTEF POTEI SMAP2	2.96e-04	247	48	5	int:PFDN2
Interaction	ATPSCKMT interactions	POTEF POTEI	3.01e-04	11	48	2	int:ATPSCKMT
Interaction	CRX interactions	NCOA2 NCOA3 ZNF217 SMAP2 EP300	3.36e-04	254	48	5	int:CRX
Interaction	SOX15 interactions	NCOA2 NCOA3 SRRM2 EP300	3.52e-04	141	48	4	int:SOX15
Interaction	SCIN interactions	POTEF ACTA1 POTEI	3.57e-04	58	48	3	int:SCIN
Interaction	PNPLA8 interactions	ACTA1 KAT6A BAG6	3.57e-04	58	48	3	int:PNPLA8
Interaction	NR1H3 interactions	NCOA3 NR3C1 EP300	3.57e-04	58	48	3	int:NR1H3
Interaction	EP300 interactions	NCOA2 FOXO1 NCOA3 AKAP8 ATR ACTA1 KAT6A NR3C1 SRRM2 BAG6 EP300	3.63e-04	1401	48	11	int:EP300
Interaction	S100A4 interactions	BBX ACTA1 POTEI BAG6	3.81e-04	144	48	4	int:S100A4
Interaction	ETS2 interactions	NCOA3 NR3C1 EP300	4.14e-04	61	48	3	int:ETS2
Interaction	MED23 interactions	NCOA2 MED12L PNISR BAG6 EP300	4.16e-04	266	48	5	int:MED23
Interaction	NR3C1 interactions	SCFD2 NCOA2 ACSL4 NCOA3 CAMK2D NR3C1 MAML3 TMEM200A EP300	4.24e-04	974	48	9	int:NR3C1
Interaction	TTLL9 interactions	NR3C1 EP300	4.26e-04	13	48	2	int:TTLL9
Interaction	GC interactions	POTEF ACTA1 POTEI	4.35e-04	62	48	3	int:GC
Interaction	H4C16 interactions	NCOA2 NCOA3 KAT6A EP300	4.68e-04	152	48	4	int:H4C16
Interaction	ROBO4 interactions	NR3C1 EP300	4.96e-04	14	48	2	int:ROBO4
Interaction	TTC5 interactions	CAMK2D NR3C1 EP300	4.99e-04	65	48	3	int:TTC5
Interaction	CREBBP interactions	NCOA2 FOXO1 NCOA3 TNFSF10 KAT6A NR3C1 EP300	5.06e-04	599	48	7	int:CREBBP
Cytoband	2q21.1	POTEE FAM168B POTEF POTEI	6.41e-07	58	53	4	2q21.1
Cytoband	Ensembl 112 genes in cytogenetic band chr1p34	SLC6A9 KLF18 GRIK3 UROD SMAP2	2.32e-05	294	53	5	chr1p34
Cytoband	Ensembl 112 genes in cytogenetic band chr2q21	POTEE FAM168B POTEF POTEI	2.90e-05	151	53	4	chr2q21
Cytoband	11q22.3	ACAT1 ZC3H12C	1.20e-03	44	53	2	11q22.3
Cytoband	Ensembl 112 genes in cytogenetic band chr11q22	ACAT1 ZC3H12C	6.86e-03	107	53	2	chr11q22
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	NCOA2 NCOA3 KAT6A KAT6B EP300	1.43e-10	17	36	5	486
GeneFamily	Ankyrin repeat domain containing\|POTE ankyrin domain containing	POTEE POTEF POTEI	2.05e-06	13	36	3	685
GeneFamily	Olfactory receptors, family 11	OR11H1 OR11H12 OR11H2	1.25e-05	23	36	3	159
GeneFamily	Zinc fingers C2HC-type\|PHD finger proteins\|Lysine acetyltransferases	KAT6A KAT6B	4.55e-04	16	36	2	66
GeneFamily	Ataxins\|Trinucleotide repeat containing	NCOA3 MAML3	1.12e-03	25	36	2	775
GeneFamily	Ankyrin repeat domain containing	POTEE POTEF POTEI	1.22e-02	242	36	3	403
GeneFamily	PHD finger proteins	KAT6A KAT6B	1.38e-02	90	36	2	88
Coexpression	DAZARD_RESPONSE_TO_UV_NHEK_DN	FOXO1 NCOA3 BBX KAT6A ZNF217 KAT6B PNISR	2.07e-06	300	52	7	M8702
Coexpression	GSE23505_UNTREATED_VS_4DAY_IL6_IL1_TGFB_TREATED_CD4_TCELL_DN	ROMO1 ACAT1 CAMK2D ZNF217 TMEM200A MSI2	2.78e-06	200	52	6	M7868
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	NCOA3 BBX ATR KAT6A NR3C1 KAT6B PNISR MEIS2	3.56e-06	466	52	8	M13522
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	FOXO1 ACSL4 NCOA3 SYNRG BBX ATR KAT6A ZNF217 NR3C1 KAT6B PNISR SMAP2 EP300	4.93e-06	1492	52	13	M40023
Coexpression	EPPERT_HSC_R	FOXO1 KAT6A PNISR TMEM200A MSI2	5.34e-06	127	52	5	M19231
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	NCOA2 ACSL4 NCOA3 BBX ATR KAT6A NR3C1 KAT6B PNISR MEIS2	5.97e-06	856	52	10	M4500
Coexpression	IVANOVA_HEMATOPOIESIS_STEM_CELL	NCOA2 FAM168B AGXT ZC3H12C MSI2	4.03e-05	193	52	5	M6813
Coexpression	IVANOVA_HEMATOPOIESIS_STEM_CELL	NCOA2 FAM168B AGXT ZC3H12C MSI2	4.34e-05	196	52	5	MM667
Coexpression	NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN	FOXO1 BBX FAM168B AKAP8 KAT6A PNISR EP300 MSI2	5.41e-05	680	52	8	M41089
Coexpression	FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	NCOA2 ACSL4 NCOA3 BBX FAM168B TNFSF10 PNISR	1.24e-04	568	52	7	M4023
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_1000	NCOA2 ACSL4 GAD1 AKAP8 ACTA1 ADGRB3 MED12L ZC3H12C NR3C1 KAT6B MEIS2 MSI2	1.35e-06	983	48	12	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_2500_k-means-cluster#5	NCOA2 ACSL4 SYNRG AKAP8 ADGRB3 MED12L ZC3H12C KAT6B TMEM200A MEIS2	1.63e-06	654	48	10	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_1000_k-means-cluster#2	NCOA2 ACSL4 AKAP8 ADGRB3 MED12L ZC3H12C KAT6B	8.41e-06	328	48	7	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_1000_K2
ToppCell	facs-Brain_Myeloid-Hippocampus\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KAT6A MED12L NR3C1 PNISR MAML3	3.52e-06	195	53	5	a1478021a3ed0e779716393124ca2a7770c433b7
ToppCell	tumor_Lung-T/NK_cells-Exhausted_Tfh\|T/NK_cells / Location, Cell class and cell subclass	TNFSF10 ZC3H12C NR3C1 SMAP2 MSI2	3.61e-06	196	53	5	5a0b5aeff7e535781ea2a4c85799bb468afcb6f8
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Tubular-6\|TCGA-Stomach / Sample_Type by Project: Shred V9	FRK AKAP8 ATR SRRM2	3.84e-05	159	53	4	655c0749c238bd68cb797adb83e25a23b8a3cc9d
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	3.94e-05	160	53	4	2d391ba6f7adb55dfa89feecc10cc9ce97e5fe74
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	3.94e-05	160	53	4	8bcdbcfdf1e0ace6053e8de82762f6e2f86bba7a
ToppCell	nucseq-Immune-Hematopoietic-Granulocytic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ACSL4 MED12L MAML3 MEIS2	4.44e-05	165	53	4	37615622c736e43260c38016e7c9e565ac97a3e8
ToppCell	nucseq-Immune-Hematopoietic-Granulocytic-Mast/Basophil\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ACSL4 MED12L MAML3 MEIS2	4.44e-05	165	53	4	640bb71e74a61df2fcb01ceeabe4c493ef836b21
ToppCell	nucseq-Immune-Hematopoietic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ACSL4 MED12L MAML3 MEIS2	4.44e-05	165	53	4	f3df74b5763130c71c0a482a3a23f6b22acc2892
ToppCell	Mild/Remission-B_naive-4\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	FOXO1 CAMK2D KAT6A SMAP2	4.87e-05	169	53	4	c3a6179a64589a370108fea809b157839347759c
ToppCell	3'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_3_(BCAN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FOXO1 ACSL4 ADGRB3 GRIK3	4.87e-05	169	53	4	2456b3e7776e8a2214972be1b4d66a3ca5480ae0
ToppCell	TCGA-Brain-Primary_Tumor-Glioblastoma-Primary_GBM-11\|TCGA-Brain / Sample_Type by Project: Shred V9	POTEE POTEF POTEI	5.83e-05	63	53	3	d7dc1356a60cb527fe668328d5375f352239d911
ToppCell	droplet-Liver-LIVER_NPC-30m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GAD1 TNFSF10 PLXNA4 MAML3	6.09e-05	179	53	4	025d414ec88d5680d99c8173e70ee3bb0b694f74
ToppCell	Control-Endothelial-Endothelial-Activated_Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 KAT6A ZC3H12C MEIS2	6.64e-05	183	53	4	e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCell	LPS-IL1RA\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ACSL4 TNFSF10 KAT6A ZC3H12C	6.78e-05	184	53	4	c066c2ec4f0f1d6eb183fca5c7bb0cd45c9950dc
ToppCell	Control-Endothelial-Endothelial-Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 KAT6A ZC3H12C MEIS2	7.22e-05	187	53	4	ea9d34bcd3bd1f36745846309ede349773de501a
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	7.37e-05	188	53	4	bc089cd73d283ed7d2ecbb3936673b4edc89f666
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	7.52e-05	189	53	4	977a813e5d7a5a561c1fced2bbf21c20056b88d8
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	7.68e-05	190	53	4	e252e925600e6457fa6e362a55217f4cffa75cdb
ToppCell	LV-08._Macrophage\|World / Chamber and Cluster_Paper	MED12L SMAP2 MS4A4E MAML3	7.83e-05	191	53	4	e7a0bc46ba9ba772636a583f3387748418e18832
ToppCell	COPD-Lymphoid-T_Regulatory\|Lymphoid / Disease state, Lineage and Cell class	NCOA2 FOXO1 ZC3H12C MSI2	7.83e-05	191	53	4	3ae18bc4e3dff49b5d5958da8ebc3f747274b69c
ToppCell	Control-Endothelial-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 KAT6A ZC3H12C MEIS2	8.15e-05	193	53	4	aff0649c73c634bc6ff0dc7759b4693a9236bf05
ToppCell	Control-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 KAT6A ZC3H12C MEIS2	8.15e-05	193	53	4	c5f9fe03e64c211d4bcd4959e5b32f14841e336a
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-NPC-like-NPC-like_neural-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	POTEE PLXNA4 MAML3 MEIS2	8.15e-05	193	53	4	088c8b1e968f5356502347eaabdc6b1b1d4befd0
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MED12L MSI2	8.49e-05	195	53	4	a38d9dc6192aea673d96fda6b25e81223fda3abf
ToppCell	Control-Lymphoid-T\|Lymphoid / Disease state, Lineage and Cell class	FOXO1 CAMK2D MED12L NR3C1	8.49e-05	195	53	4	6687e579582d7a239bee80846de0cf827a6f6a62
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-Trm_Th1/Th17\|Liver / Manually curated celltypes from each tissue	FOXO1 NR3C1 SMAP2 TMEM200A	8.49e-05	195	53	4	480cc62ee1e5b1aaf6b62be6e5afd7a81236a1b0
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 ADGRB3 MAML3 MSI2	9.18e-05	199	53	4	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	MS-IIF-Others-HSPC\|IIF / Disease, condition lineage and cell class	MED12L UROD MEIS2 MSI2	9.18e-05	199	53	4	3384db80f6024bcabe2625f24d5f4e0d3d8caa7e
ToppCell	Control_saline-Endothelial-Endothelial-Activated_Alv_Cap\|Control_saline / Treatment groups by lineage, cell group, cell type	NCOA3 TNFSF10 KAT6A NR3C1	9.36e-05	200	53	4	be55cef682ba87250dad97689332c8820b3a7420
ToppCell	LPS_only-Endothelial-Endothelial-Alv_Cap\|LPS_only / Treatment groups by lineage, cell group, cell type	TNFSF10 KAT6A ZC3H12C MEIS2	9.36e-05	200	53	4	432384faeade8e609154fab3d96c955a8ec868dd
ToppCell	Neuronal-Inhibitory-iA-iA_1(SST_PAX6)\|Neuronal / cells hierarchy compared to all cells using T-Statistic	FOXO1 GAD1 MAML3 MSI2	9.36e-05	200	53	4	d0167f96314be78b6d867bbcc6e4396071d931b8
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	NCOA3 TNFSF10 KAT6A ZC3H12C	9.36e-05	200	53	4	79e51afb57ca38aacebd0298e5e727b55c0cfff9
ToppCell	TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Lobular_Carcinoma-9\|TCGA-Breast / Sample_Type by Project: Shred V9	POTEE POTEF POTEI	1.69e-04	90	53	3	96e836c7a1df279ac812b7c3aa75e6b81b614244
ToppCell	PND07-28-samps-Myeloid-Macrophage-macrophage-A\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	TESMIN ADGRB3 KLF18	3.21e-04	112	53	3	d21cfcb04a27cc9fb74e0c2afa8a8cdfb886ae21
ToppCell	COVID-19-kidney-Technical/muscle_(EC)\|kidney / Disease (COVID-19 only), tissue and cell type	POTEF ADGRB3 SEL1L2	6.04e-04	139	53	3	64c35411bbe67acb5010dadc4b0b1be0f8b17737
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 MED12L MSI2	6.42e-04	142	53	3	5b6b0c611c83b23ef7289854a515b78f6cf84500
ToppCell	tumor_Lung-Myeloid_cells-Pleural_Mac\|Myeloid_cells / Location, Cell class and cell subclass	SCFD2 CLDN18 ADGRB3	6.96e-04	146	53	3	8b2d104fdb0fdb09410450c6c651e1edb00cae44
ToppCell	Mild/Remission-B_naive-4\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	FOXO1 CAMK2D SMAP2	7.24e-04	148	53	3	dd5e1bc02824e743e1c030a303e32f27a359a8ca
ToppCell	metastatic_Brain-T/NK_cells-CD8+/CD4+_Mixed_Th\|T/NK_cells / Location, Cell class and cell subclass	BBX SMAP2 MEIS2	7.39e-04	149	53	3	04c696f5102b0fff7d80e0f8d12a3119b2b81898
ToppCell	Adult-Immune-dendritic_cell-D122\|Adult / Lineage, Cell type, age group and donor	PLXNA4 MED12L MS4A4E	8.13e-04	154	53	3	64a4686586d08b1e9632dde917b472ac660de2d3
ToppCell	COVID-19-Mast_cells\|COVID-19 / group, cell type (main and fine annotations)	MED12L MAML3 MEIS2	8.43e-04	156	53	3	159504d43421ee83b9ab484816333ae549c9c2fd
ToppCell	COVID-19-Mast_cells-Mast_cells\|COVID-19 / group, cell type (main and fine annotations)	MED12L MAML3 MEIS2	8.43e-04	156	53	3	bc10b94673184ef384c6665b16a1209a8975a4f1
ToppCell	Control-Endothelial-Epi-like-Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 ACTA1 SEL1L2	8.59e-04	157	53	3	2c369660c752c0fb3bd798a561d3359e2f9aa983
ToppCell	Control-Endothelial-Epi-like\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TNFSF10 ACTA1 SEL1L2	8.59e-04	157	53	3	4d02c50d5d1b892ea241e98724386d8a5a156a46
ToppCell	severe_COVID-19-pDC\|World / disease group, cell group and cell class (v2)	ACTA1 PLXNA4 MED12L	8.91e-04	159	53	3	e1c48c4ceda116826819ff9adeed7bad6a58844d
ToppCell	severe_COVID-19-pDC\|severe_COVID-19 / disease group, cell group and cell class (v2)	ACTA1 PLXNA4 MED12L	8.91e-04	159	53	3	ea5088d27e42b8850455764d53b757ea8d8f14bc
ToppCell	normal_Pleural_Fluid-B_lymphocytes-Undetermined\|normal_Pleural_Fluid / Location, Cell class and cell subclass	SRRM2 PNISR SMAP2	9.07e-04	160	53	3	5744cd30709f38e84f7ec8893dc19d7a288b465a
ToppCell	Leuk-UTI-Myeloid-tDC\|Leuk-UTI / Disease, Lineage and Cell Type	BBX PLXNA4 MED12L	9.24e-04	161	53	3	51b9f60986ed2e8e2297d31c80462c3ab65a2e5e
ToppCell	facs-Marrow-T-cells-24m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC6A9 UROD TMEM200A	9.24e-04	161	53	3	1ce40a6d0f0b9870e7ddb3d607668adcbd3dd1d3
ToppCell	facs-Marrow-T-cells-24m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC6A9 UROD TMEM200A	9.24e-04	161	53	3	79a4a81963c92ade5b6910816a440dc3c233ead2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 TMEM200A MEIS2	9.24e-04	161	53	3	1b805f77790aeb8a71b08bfac2fe2eed7343258f
ToppCell	10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	KAT6A PNISR MSI2	9.41e-04	162	53	3	b4535bcb3f469bc139e73f1122f4070013e5a1de
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	KLF18 GRIK3 MEIS2	9.57e-04	163	53	3	218b9ba099cb27aa91c6b73bf89b44895f5dddc3
ToppCell	facs-Liver-Non-hepatocytes-3m-Myeloid-neutrophil\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NHSL2 ACTA1 MED12L	9.74e-04	164	53	3	8e6dbddacd56a07769163813e3ebfad13302bb62
ToppCell	LV-16._Neuronal\|World / Chamber and Cluster_Paper	FOXO1 ADGRB3 GRIK3	9.92e-04	165	53	3	6ed52cb756d21addf46c7f6c457458b01339fe04
ToppCell	tumor_Lymph_Node_/_Brain-T/NK_cells-Exhausted_Tfh\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	FOXO1 NR3C1 TMEM200A	1.01e-03	166	53	3	c73fce59256ad501864f44f76cfae2fc33b3777e
ToppCell	Children_(3_yrs)-Mesenchymal-myofibroblast_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FOXO1 PLXNA4 TMEM200A	1.01e-03	166	53	3	94636dbc039f794c735960c3425e00bdd5523602
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	BBX AKAP8 MAML3	1.01e-03	166	53	3	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	wk_20-22-Hematologic-Myeloid-Mast\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	ACSL4 TNFSF10 MEIS2	1.01e-03	166	53	3	004ab6a1425d812c7ce572205875fd702d4a9659
ToppCell	390C-Lymphocytic-NK_cells-NK_cell_D3\|NK_cells / Donor, Lineage, Cell class and subclass (all cells)	MED12L MAML3 TMEM200A	1.04e-03	168	53	3	6501495b7ad252af330b18011696c43031541018
ToppCell	356C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-2\|356C / Donor, Lineage, Cell class and subclass (all cells)	POTEI NR3C1 TMEM200A	1.04e-03	168	53	3	9d6ca10c272aea28082c09d469940f7232f6461c
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NHSL2 MS4A4E MAML3	1.04e-03	168	53	3	d60f7cd8269f373827f49c7785002cb38e4570a9
ToppCell	COVID-19-Heart-Neuronal\|COVID-19 / Disease (COVID-19 only), tissue and cell type	FOXO1 ADGRB3 GRIK3	1.04e-03	168	53	3	88c2c574f428c2502b5fe099bd73b0758f668ef6
ToppCell	Control-T_cells-Tregs\|Control / group, cell type (main and fine annotations)	FOXO1 SMAP2 MSI2	1.06e-03	169	53	3	e1e0983f31ec81b3fad5f9c6140d17f03f81a5dc
ToppCell	LV-16._Neuronal\|LV / Chamber and Cluster_Paper	FOXO1 ADGRB3 GRIK3	1.06e-03	169	53	3	a8fc8ab0f0757e939e213efb61c03cfe390bf7d2
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NHSL2 MS4A4E MAML3	1.06e-03	169	53	3	ccd98f9005aa0a88bd49f153be4e7200cc3dd0ac
ToppCell	COVID-19-lung-MAST\|lung / Disease (COVID-19 only), tissue and cell type	ACSL4 MAML3 MEIS2	1.08e-03	170	53	3	e90f18e5462381b38e918442b38b1c8105291908
ToppCell	Severe-B_naive-11\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	CAMK2D PNISR SMAP2	1.10e-03	171	53	3	7c2699f19ca38414447a286f7658f507882d57c2
ToppCell	Control-Myeloid-Mast\|World / Disease state, Lineage and Cell class	ACSL4 MAML3 MEIS2	1.10e-03	171	53	3	ed8e61d524f4cddc6084b261175df54d2a64a60f
ToppCell	356C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-2\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	POTEI NR3C1 TMEM200A	1.10e-03	171	53	3	bdd30100b74e012eec3090799c22635aa57fa91d
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 MAML3 TMEM200A	1.12e-03	172	53	3	553701349444eb366df3c11f54bb093434f153c6
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 MAML3 TMEM200A	1.12e-03	172	53	3	08a3fe536b1b064c5ee7779bc2b1115a5963a26b
ToppCell	Immune-mast_cell\|World / Lineage, Cell type, age group and donor	ACSL4 MED12L MEIS2	1.12e-03	172	53	3	6e8e0aac5a20dbc789bf8c6916833bb8709a411a
ToppCell	5'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid-CLC+_Mast_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ACSL4 TNFSF10 MS4A4E	1.12e-03	172	53	3	2ab720a4c96073339a1f8b95ec7699682df98acf
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 GAD1 MSI2	1.14e-03	173	53	3	4bc6d93716f093b460c8b047199db8cab5fea720
ToppCell	COVID-19-Heart-Neuronal\|Heart / Disease (COVID-19 only), tissue and cell type	FOXO1 ADGRB3 GRIK3	1.14e-03	173	53	3	6fb5f9e6536a5d57fd8e6657b494047a2d0bc9c7
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Neuronal-Glial_immature-Glia_1_(DHH+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ADGRB3 GRIK3 ZC3H12C	1.14e-03	173	53	3	922356a5b4c84607318ac24d7caa2e235b72b066
ToppCell	droplet-Lung-LUNG-1m-Myeloid-Ccr7+_Dendritic\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATR PLXNA4 ZC3H12C	1.16e-03	174	53	3	7be0c6248e77f2d0260b852b01e17892f7828f1b
ToppCell	356C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	POTEI NR3C1 TMEM200A	1.16e-03	174	53	3	99d7421ad5eafe7751ef90698a92f683aa33bca8
ToppCell	5'-GW_trimst-2-LymphNode-Hematopoietic-Myeloid-CLC+_Mast_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ACSL4 TESMIN TNFSF10	1.16e-03	174	53	3	36080fa12497faa752ff07ae52cd3864053eafef
ToppCell	390C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	FOXO1 TNFSF10 TMEM200A	1.17e-03	175	53	3	6374ab186d7ccf7f6dfb858267edba8962789e15
ToppCell	Control-B_cells-Plasma_cells\|Control / group, cell type (main and fine annotations)	NCOA3 SMAP2 MSI2	1.17e-03	175	53	3	fb23858cfce71509cafbe0d9728e678012ff2962
ToppCell	droplet-Lung-1m-Hematologic-myeloid-myeloid_dendritic_cell-Ccr7+_dendritic\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ATR PLXNA4 ZC3H12C	1.17e-03	175	53	3	1b910c08d2bfbcc77431ee66103e63a11a9d39fe
ToppCell	3'-GW_trimst-2-SmallIntestine-Endothelial-lymphatic_endothelial-LEC3_(ADGRG3+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	GAD1 FRK NHSL2	1.17e-03	175	53	3	43be63976da5ad0764d24d90919a77ce46068f52
ToppCell	COVID-19-lung-MAST\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ACSL4 MAML3 MEIS2	1.19e-03	176	53	3	473c45a381ca109207d66ed1635668b391ea0e1f
ToppCell	Control-B_cells\|Control / group, cell type (main and fine annotations)	NCOA3 SMAP2 MSI2	1.19e-03	176	53	3	9125caa27bf790f6b1b960a86c09b4bcb1b58641
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS-Exc_L5-6_THEMIS_THTPA\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CLDN18 NHSL2 TMEM200A	1.19e-03	176	53	3	e788c7e0b2bfde31fddbf9e04d07140f8b964857
ToppCell	Brain_organoid-organoid_Velasco_nature-3_mon-Neuronal-Immature_Interneurons\|3_mon / Sample Type, Dataset, Time_group, and Cell type.	GAD1 MEIS2 MSI2	1.19e-03	176	53	3	62870115e31170c8b42eec57c709e0fe32388b37
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Hematopoietic-Myeloid-CLC+_Mast_cell\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ACSL4 TNFSF10 MS4A4E	1.19e-03	176	53	3	183ba1aa5cf594b88ec08e0e41241668b51256a9
ToppCell	5'-GW_trimst-2-SmallIntestine-Endothelial-lymphatic_endothelial-LEC2_(MADCAM1+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FOXO1 GAD1 TNFSF10	1.21e-03	177	53	3	76f5df101c693e5fa61554244d877fc8169ee66f
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ACSL4 CLDN18 GAD1	1.21e-03	177	53	3	c9e8149639551a4c8daa90fcb2b895fdcff2e2ba
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CAMK2D GRIK3 MEIS2	1.21e-03	177	53	3	4c069f0d044a96118090b85ca592a21d6b5d9399
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_CA4\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FOXO1 GAD1 MAML3	1.23e-03	178	53	3	08b4a497aca0aeabf4f6a8a55c05b56417b69e78
ToppCell	droplet-Limb_Muscle-MUSCLE-30m\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF10 NR3C1 SRRM2	1.23e-03	178	53	3	01dafd19de04eff459253eaa9a35debf8f3deedf
ToppCell	T_cells-TFH-like_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	ZC3H12C NR3C1 MSI2	1.23e-03	178	53	3	e2ae43e5ec31de6197f2cbd6089f944adbf0a163
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell-B_cell\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NCOA3 SMAP2 EP300	1.25e-03	179	53	3	fad1fbee002fcd424c03460d695559060ce41a3f
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GAD1 NHSL2 MEIS2	1.25e-03	179	53	3	a3922476f33d2e4137a12dbda21a1703dff79684
ToppCell	COVID-19-kidney-REN+Pericyte\|kidney / Disease (COVID-19 only), tissue and cell type	ADGRB3 TMEM200A MEIS2	1.25e-03	179	53	3	342c1cc4444f51b8dcb30d3adc98285a25669c6e
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NCOA3 SMAP2 EP300	1.25e-03	179	53	3	6d4e4b64e633b2ae8514ffa1e45829d6508dac54
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell-B_cell-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NCOA3 SMAP2 EP300	1.25e-03	179	53	3	61a7cc01fae4115325fce0efaa5bacf8f9af5ba2
Drug	nanaomycin A	NCOA3 ACTA1 UROD	1.26e-06	10	51	3	CID000040586
Drug	AC1L1COZ	NCOA3 ACAT1 KAT6A KAT6B EP300	1.76e-06	90	51	5	CID000001996
Drug	glycine	NCOA2 AGXT SLC6A5 UROD BAG6 EP300	2.09e-06	169	51	6	CID000000750
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	NCOA2 AKAP8 KAT6B SRRM2 PNISR EP300	2.16e-06	170	51	6	1050_DN
Drug	HC toxin from Helminthosporium carbonum; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	NCOA2 AKAP8 KAT6B SRRM2 PNISR EP300	2.47e-06	174	51	6	909_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA	NCOA2 AKAP8 KAT6B SRRM2 PNISR EP300	2.56e-06	175	51	6	1014_DN
Drug	SAHA; Down 200; 10uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR EP300	2.73e-06	177	51	6	1645_DN
Drug	TiNi	NCOA3 KAT6A KAT6B SRRM2 EP300	2.96e-06	100	51	5	CID000159408
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	SYNRG KAT6A ZNF217 NR3C1 KAT6B EP300	3.01e-06	180	51	6	4541_DN
Drug	DL-Serine	SLC6A9 AGXT SLC6A5 UROD SRRM2 PNISR	6.02e-06	203	51	6	CID000000617
Drug	butyrate	NCOA3 GAD1 ACAT1 TNFSF10 ACTA1 KAT6A SLC6A5 NR3C1 KAT6B EP300	6.49e-06	767	51	10	CID000000264
Drug	pyridoxamine 5'-phosphate	GAD1 AGXT NR3C1 UROD	7.52e-06	56	51	4	CID000001053
Drug	AC1Q68Z5	NCOA3 ACAT1 KAT6A UROD KAT6B MAML3 EP300	2.32e-05	386	51	7	CID000000181
Drug	AC1ND2OB	NCOA2 FOXO1 NCOA3 ZNF217 NR3C1 EP300	2.73e-05	265	51	6	CID004568637
Drug	9,10-dihydrophenanthrene	NCOA3 NR3C1	2.94e-05	4	51	2	CID000013058
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	3.18e-05	163	51	5	7453_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B PNISR EP300	3.38e-05	165	51	5	5625_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 GAD1 AKAP8 KAT6B SRRM2	3.58e-05	167	51	5	3979_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	3.68e-05	168	51	5	3868_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.12e-05	172	51	5	1072_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.12e-05	172	51	5	2794_DN
Drug	Glycine	SLC6A9 AGXT SLC6A5	4.12e-05	30	51	3	DB00145
Drug	anacardic acid	KAT6A KAT6B EP300	4.12e-05	30	51	3	CID000167551
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.23e-05	173	51	5	5336_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.35e-05	174	51	5	5065_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.47e-05	175	51	5	6316_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.47e-05	175	51	5	6736_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.47e-05	175	51	5	3787_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.59e-05	176	51	5	6546_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.59e-05	176	51	5	6932_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	4.59e-05	176	51	5	1535_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.72e-05	177	51	5	6434_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B PNISR EP300	4.72e-05	177	51	5	7047_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.72e-05	177	51	5	3227_DN
Drug	alpha-ketoisovalerate	CAMK2D KAT6A AGXT KAT6B	4.74e-05	89	51	4	CID000000049
Drug	CoA group	ACSL4 NCOA3 ACAT1 ACTA1 KAT6A KAT6B EP300	4.82e-05	433	51	7	CID000000317
Drug	SAHA; Down 200; 10uM; PC3; HT_HG-U133A	AKAP8 KAT6B SRRM2 PNISR EP300	4.85e-05	178	51	5	4444_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.85e-05	178	51	5	4710_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	4.98e-05	179	51	5	6609_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B PNISR EP300	5.11e-05	180	51	5	3688_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 EP300	5.11e-05	180	51	5	4821_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 NR3C1 KAT6B SRRM2	5.25e-05	181	51	5	3643_DN
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; PC3; HT_HG-U133A	NCOA2 NCOA3 SYNRG KAT6B PNISR	5.25e-05	181	51	5	1791_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A	NCOA2 AKAP8 KAT6B SRRM2 PNISR	5.39e-05	182	51	5	1951_DN
Drug	pyridoxal 5'-phosphate	ACSL4 GAD1 AGXT PSMB6 NR3C1 UROD	5.55e-05	301	51	6	CID000001051
Drug	melatonin	NCOA3 KAT6A GRIK3 NR3C1 UROD KAT6B EP300	5.57e-05	443	51	7	CID000000896
Drug	AC1L2E0P	NCOA2 NCOA3 KAT6A NR3C1 KAT6B EP300	6.19e-05	307	51	6	CID000019390
Drug	gabaculine	GAD1 AGXT UROD	6.59e-05	35	51	3	CID000003445
Drug	glutamin	FOXO1 NCOA3 KAT6A PSMB6 NR3C1 KAT6B EP300	7.15e-05	461	51	7	CID000000738
Drug	L-165041	NR3C1 UROD EP300	7.18e-05	36	51	3	CID006603901
Drug	butamben	NCOA2 NCOA3	7.34e-05	6	51	2	ctd:C004605
Drug	B on A	NCOA2 NCOA3 SYNRG KAT6A NR3C1 KAT6B EP300	7.44e-05	464	51	7	CID000007104
Drug	Tocopherol (R,S) [10191-41-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	NCOA2 ACSL4 KAT6B SRRM2 PNISR	7.47e-05	195	51	5	4961_DN
Drug	Cyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; PC3; HT_HG-U133A	FOXO1 CLDN18 SLC6A9 ACTA1 AGXT	7.65e-05	196	51	5	6740_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 NR3C1 PNISR EP300	8.03e-05	198	51	5	3332_DN
Drug	Moroxidine hydrochloride [3160-91-6]; Up 200; 19.2uM; MCF7; HT_HG-U133A	NCOA2 FRK KAT6A SLC6A5 SRRM2	8.22e-05	199	51	5	1527_UP
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; MCF7; HT_HG-U133A	NCOA2 ACSL4 FRK KAT6A SRRM2	8.22e-05	199	51	5	2319_DN
Drug	CGS 19755	SLC6A9 SLC6A5 GRIK3	8.45e-05	38	51	3	CID000068736
Drug	Dermatop	AGXT NR3C1	1.03e-04	7	51	2	CID000052421
Drug	AC1N0FHX	KAT6A EP300	1.37e-04	8	51	2	CID003916227
Drug	AC1LCVO8	KAT6A KAT6B	1.37e-04	8	51	2	CID000656891
Drug	S-adenosylmethionine	NCOA2 ACSL4 GAD1 ACAT1 UROD EP300	1.37e-04	355	51	6	CID000001079
Drug	AC1L1G5B	KAT6A KAT6B EP300	1.50e-04	46	51	3	CID000003531
Drug	AC1O5TPK	NCOA2 TNFSF10 NR3C1	2.04e-04	51	51	3	CID006440511
Drug	AC1LADJ6	SLC22A6 TNFSF10 ACTA1 UROD	2.06e-04	130	51	4	CID000486032
Drug	CKI-7	FOXO1 TNFSF10 CAMK2D	2.29e-04	53	51	3	CID000129236
Drug	pyridoxal	GAD1 SLC22A6 AGXT UROD	2.38e-04	135	51	4	CID000001050
Drug	glutamate	SLC6A9 GAD1 CAMK2D ACTA1 AGXT SLC6A5 GRIK3 NR3C1 UROD	2.54e-04	962	51	9	CID000000611
Drug	2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	NCOA2 NCOA3	2.67e-04	11	51	2	ctd:C061137
Drug	C04424	KAT6A KAT6B	2.67e-04	11	51	2	CID011953835
Drug	deoxypyridoxine-P	GAD1 NR3C1 UROD	2.84e-04	57	51	3	CID000095687
Drug	3-Hydroxybutanoyl-Coenzyme A	ACAT1 KAT6A KAT6B	2.84e-04	57	51	3	CID000000521
Drug	1-norokadaone	CAMK2D NR3C1	3.20e-04	12	51	2	CID003309928
Drug	C05118	KAT6A KAT6B	3.20e-04	12	51	2	CID000440565
Drug	C05119	KAT6A KAT6B	3.20e-04	12	51	2	CID000440566
Drug	corticoid	NCOA2 NR3C1	3.20e-04	12	51	2	CID000066249
Drug	dexamethasone oxetanone	NCOA2 NR3C1	3.20e-04	12	51	2	CID000063042
Drug	iclaprim	NCOA2 NR3C1 EP300	3.65e-04	62	51	3	CID000213043
Drug	dihydroxy-vitamin D3	NCOA2 NCOA3	3.78e-04	13	51	2	ctd:C118756
Drug	AC1L9EUB	KAT6A KAT6B	3.78e-04	13	51	2	CID000443527
Drug	L-cycloserine	SLC6A9 AGXT SLC6A5	4.39e-04	66	51	3	CID000000401
Drug	AC1L9EU8	KAT6A KAT6B	4.40e-04	14	51	2	CID000443526
Drug	AC1LCVO5	KAT6A KAT6B	4.40e-04	14	51	2	CID000656890
Drug	pyrroloquinoline quinone	GAD1 ACAT1 UROD	4.58e-04	67	51	3	CID000001024
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	4.65e-04	161	51	4	4768_DN
Drug	galangin	NCOA2 NCOA3 EP300	4.79e-04	68	51	3	ctd:C037032
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	AKAP8 KAT6B SRRM2 PNISR	4.87e-04	163	51	4	7285_DN
Drug	dicyclohexyl phthalate	NCOA2 NCOA3 SLC22A6 ATR ACAT1 ACTA1 PLXNA4 NR3C1	5.02e-04	836	51	8	ctd:C036042
Drug	C11998	NCOA2 NR3C1	5.07e-04	15	51	2	CID005282036
Drug	ferric nitrate nonahydrate	ACTA1 UROD	5.07e-04	15	51	2	CID000024527
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.10e-04	165	51	4	6085_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.10e-04	165	51	4	2835_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B PNISR	5.21e-04	166	51	4	7324_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.45e-04	168	51	4	6820_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B EP300	5.58e-04	169	51	4	5231_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.58e-04	169	51	4	5572_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.58e-04	169	51	4	6064_DN
Drug	N(omega)-hydroxy-L-arginine	NCOA2 NR3C1 UROD	5.66e-04	72	51	3	CID000123895
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 AKAP8 KAT6B SRRM2	5.70e-04	170	51	4	3791_DN
Drug	In-G	NCOA3 KAT6A KAT6B EP300	5.70e-04	170	51	4	CID000446054
Disease	Prostatic Neoplasms	NCOA2 FOXO1 ACSL4 NCOA3 ATR TNFSF10 KAT6A NR3C1	5.29e-06	616	47	8	C0033578
Disease	Malignant neoplasm of prostate	NCOA2 FOXO1 ACSL4 NCOA3 ATR TNFSF10 KAT6A NR3C1	5.29e-06	616	47	8	C0376358
Disease	cognitive function measurement	NCOA2 GAD1 FRK BBX PLXNA4 MED12L NR3C1 MAML3 MEIS2 MSI2	7.10e-05	1434	47	10	EFO_0008354
Disease	choroid plexus volume measurement	FRK PLXNA4	8.88e-05	9	47	2	EFO_0010293
Disease	prostate cancer (is_marker_for)	NCOA2 FOXO1 NCOA3 EP300	1.12e-04	156	47	4	DOID:10283 (is_marker_for)
Disease	Endometrial Carcinoma	ATR TNFSF10 EP300	2.09e-04	72	47	3	C0476089
Disease	Malignant neoplasm of breast	NCOA2 NCOA3 AKAP8 TNFSF10 SLC6A5 GRIK3 KAT6B EP300	2.67e-04	1074	47	8	C0006142
Disease	Adenocarcinoma of lung (disorder)	ACSL4 ATR TNFSF10 EP300	3.25e-04	206	47	4	C0152013
Disease	polycystic ovary syndrome (biomarker_via_orthology)	TNFSF10 NR3C1	5.12e-04	21	47	2	DOID:11612 (biomarker_via_orthology)
Disease	Adenoid Cystic Carcinoma	KAT6A MAML3 EP300	5.50e-04	100	47	3	C0010606
Disease	Psychotic Disorders	SLC6A9 GRIK3 NR3C1	5.66e-04	101	47	3	C0033975
Disease	breast cancer (implicated_via_orthology)	NCOA3 ATR	7.28e-04	25	47	2	DOID:1612 (implicated_via_orthology)
Disease	Unipolar Depression	ACSL4 GAD1 AKAP8 NR3C1	7.69e-04	259	47	4	C0041696
Disease	cortex volume change measurement, age at assessment	AGXT ADGRB3	9.14e-04	28	47	2	EFO_0008007, EFO_0021500
Disease	bipolar disorder (is_implicated_in)	GAD1 KAT6B	9.81e-04	29	47	2	DOID:3312 (is_implicated_in)
Disease	Depressive disorder	ACSL4 GAD1 GRIK3 NR3C1	1.15e-03	289	47	4	C0011581
Disease	white matter integrity	SCFD2 CAMK2D BAG6	1.18e-03	130	47	3	EFO_0004641

Protein segments in the cluster

Peptide	Gene	Start	Entry
MYTSGSTGRPKGVMM	ACSL4	276	O60488
MTQAGLTSPNMGMGT	EP300	126	Q09472
MSNMSASPMGVNGGV	EP300	506	Q09472
NFGMADPTQMGGLSM	BBX	196	Q8WY36
MMHMNIQDSGTQPGG	BAG6	456	P46379
MSGGTTMYPGIADRM	ACTA1	301	P68133
SMAPDYGVMGMQGAG	AKAP8	251	O43823
GMGMMDFQNSYLMTG	ADGRB3	686	O60242
GINTMSEQGMTPLMY	BTBD11	596	A6QL63
MLGMGMLGYPNFVAT	MSI2	211	Q96DH6
EGGQVYSVPMGGMMV	PSMB6	141	P28072
YSVPMGGMMVRQSFA	PSMB6	146	P28072
AMNGYSMSQPMMNSG	KAT6B	1991	Q8WYB5
GMMGTQPYAQQPMQT	KAT6B	2026	Q8WYB5
LMTYMVEGGGSSTMA	UROD	161	P06132
QGMMGGMHQKESYVG	POTEF	741	A5A3E0
GGTTMYPGMAHRMQK	POTEF	1001	A5A3E0
MVMYVSPGLGHSTGM	OR11H2	271	Q8NH07
TMPQGYTMYGTQMPL	MED12L	1936	Q86YW9
TSQPGMYNMSTGMTQ	MAML3	866	Q96JK9
YVSQGGPMGMSMAQP	MEIS2	391	O14770
MMESGTTMVGYQPQG	GAD1	546	Q99259
KVMARVGGMEYSPGM	PLXNA4	1211	Q9HCM2
MGLYMGETETKVMGN	NR3C1	86	P04150
QGMMGGMHQKESYVG	POTEE	741	Q6S8J3
GGTTMYPGMAHRMQK	POTEE	1001	Q6S8J3
GMMGSQAYTQQPMQP	KAT6A	1956	Q92794
KMPYSGMTGAQVIQM	FRK	431	P42685
THNMVNGMGPMGTEG	ATR	2516	Q13535
VMMGPNSVMSTYGSQ	FOXO1	496	Q12778
MTTMQGMEQTTPGAG	MS4A4E	1	Q96PG1
GQMTTSLDLYGGQMM	KLF18	211	A0A0U1RQI7
MMTSTGNQALYGGQM	KLF18	616	A0A0U1RQI7
FGMGSLMQQGSELMP	GRIK3	616	Q13003
GELYPTMIRQTGMGM	SLC22A6	446	Q4U2R8
TANMYTGMGGMVQTV	CLDN18	151	P56856
GNGVTMGMVAGTTMA	FAM168B	141	A1KXE4
QYMDGSGMPKTMQSE	CAMK2D	436	Q13557
MVMYVSPGLGHSTGM	OR11H1	271	Q8NG94
MVMYVSPGLGHSTGM	OR11H12	271	B2RN74
TLMSMPNYMQTGGLE	TESMIN	411	Q9Y4I5
GGLQMIGSMSKDMYQ	AGXT	41	P21549
MSVLQQAGGSMMDGP	SRRM2	2146	Q9UQ35
MNGMYTGLMGETEVK	TMEM200A	181	Q86VY9
MQPNMQGIMGMNYSS	SYNRG	56	Q9UMZ2
QGIMGMNYSSQMSQG	SYNRG	61	Q9UMZ2
MGFPMITQGGIYMFQ	SLC6A5	616	Q9Y345
GMESMGMVYSVPSSC	NHSL2	366	Q5HYW2
YTFGSAGGNMMSQMI	SEL1L2	206	Q5TEA6
MQSGGTFGTFMAIGM	ROMO1	61	P60602
MMDSQENYGSSMGGP	NCOA3	891	Q9Y6Q9
QGMMGGMHQKESYVG	POTEI	741	P0CG38
GGTTMYPGMAHRMQK	POTEI	1001	P0CG38
GGMESMSNVPYVMNR	ACAT1	151	P24752
MSMGRVTPGQLMSYI	SCFD2	376	Q8WU76
YSVIPQPGMMGNQGM	NCOA2	911	Q15596
PNGMMTTQQAGYMAG	SMAP2	351	Q8WU79
TTQQAGYMAGMAAMP	SMAP2	356	Q8WU79
PMFKGVGYGMMVVST	SLC6A9	176	P48067
TGNMPTQSLLMYMDG	ZNF217	6	O75362
MPNGQDMSTMESGPN	PNISR	61	Q8TF01
QGQYPSMMMATKNHG	ZC3H12C	556	Q9C0D7
MAMMEVQGGPSLGQT	TNFSF10	1	P50591